Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial
- 1 February 2014
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 112 (2) , 146-153.e2
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Factors affecting time required to reach maintenance dose during subcutaneous immunotherapyInternational Forum of Allergy & Rhinology, 2012
- Allergen immunotherapy: A practice parameter third updateJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adultsJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescentsJournal of Allergy and Clinical Immunology, 2011
- Phleum pratense alone is sufficient for allergen‐specific immunotherapy against allergy to Pooideae grass pollensClinical & Experimental Allergy, 2009
- Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapyJournal of Allergy and Clinical Immunology, 2009
- Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2006
- Key pollen allergens in North AmericaAnnals of Allergy, Asthma & Immunology, 2003
- Effect of tree and grass pollens and fungal spores on spring allergic rhinitis: a comparative studyAnnals of Allergy, Asthma & Immunology, 1999
- Prevalence of Sensitization to Aeroallergens in California Patients with Respiratory AllergyAnnals of Allergy, Asthma & Immunology, 1998